The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Open accessAbstract
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects. Though, tumor inherent or acquired resistance to ICIs accompanied with treatment-related toxicities hamper their clinical utility. Overall, about 60–70% of patients (e.g., melanoma and lung cancer) who received ICIs show no objective response to intervention. The resistance to ICIs mainly caused by alterations in the tumor microenvironment (TME), which in turn, supports angiogenesis and also blocks immune cell antitumor activities, facilitating tumor cells' evasion from host immunosurveillance. Thereby, it has been supposed and also validated that combination therapy with ICIs and other therapeutic means, ranging from chemoradiotherapy to targeted therapies as well as cancer vaccines, can capably compromise tumor resistance to immune checkpoint blocked therapy. Herein, we have focused on the therapeutic benefits of ICIs as a groundbreaking approach in the context of tumor immunotherapy and also deliver an overview concerning the therapeutic influences of the addition of ICIs to other modalities to circumvent tumor resistance to ICIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–302 of 302
Zhao, J., Chen, Y., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01184 · Cited by 87
Antoniotti, C., Borelli, B., Rossini, D., Pietrantonio, F., Morano, F., Salvatore, L., Lonardi, S., Marmorino, F., Tamberi, S., Corallo, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07169-6 · Cited by 87
Lévesque, S., Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., Baracco, E. E., Wang, Y., Vacchelli, E., Stoll, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657375 · Cited by 86
Helm, A., Tinganelli, W., Simoniello, P., Kurosawa, F., Fournier, C., Shimokawa, T., & Durante, M. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.09.041 · Cited by 86
CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors
Shah, K. V., Chien, A. J., Yee, C., & Moon, R. T. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.170 · Cited by 85
The Multiple Layers of the Tumor Environment
Laplane, L., Duluc, D., Larmonier, N., Pradeu, T., & Bikfalvi, A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.10.002 · Cited by 84
Sun, F., Cui, L., Li, T., Chen, S., Jun-mei, S., & Li, D. (2019) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2019.1655050 · Cited by 83
Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy
Kodumudi, K. N., Siegel, J., Weber, A. M., Scott, E. N., Sarnaik, A. A., & Pilon‐Thomas, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153053 · Cited by 81
Zheng, F., Dang, J., Zhang, H., Xu, F., Ba, D., Zhang, B., Cheng, F., Chang, A. E., Wicha, M. S., & Li, Q. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000242 · Cited by 80
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 78
PD‐1 Blockade for Improving the Antitumor Efficiency of Polymer–Doxorubicin Nanoprodrug
Gao, F., Zhang, C., Qiu, W., Dong, X., Zheng, D., Wu, W. H., & Zhang, X. (2018) · Small · doi:10.1002/smll.201802403 · Cited by 74
Reck, M., Liu, S. V., Mansfield, A. S., Mok, T. S. K., Scherpereel, A., Reinmuth, N., Garassino, M. C., Carpeño, J. D. C., Califano, R., Nishio, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz264 · Cited by 73
Wu, X., Li, J., Connolly, E. M., Liao, X., Ouyang, J., Giobbie‐Hurder, A., Lawrence, D. P., McDermott, D. F., Murphy, G. F., Zhou, J. M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0385 · Cited by 71
Wang, S., Li, H., Li, B., Xie, T., Zhu, T., Sun, L., Ren, H., & Ye, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.016 · Cited by 70
The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer
Otsuka, S., & Bebb, G. D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818dda9d · Cited by 68
Reck, M., Shankar, G., Lee, A., Coleman, S., McCleland, M. L., Papadimitrakopoulou, V. A., Socinski, M. A., & Sandler, A. B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1701439 · Cited by 68
Puzanov, I. J., Ribas, A., Robert, C., Schachter, J., Nyakas, M., DAUD, A. I., Arance, A. M., Carlino, M. S., O'Day, S. J., Long, G. V., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2288 · Cited by 67
Jiang, Z., Hsu, J. L., Li, Y., Hortobágyi, G. N., & Hung, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01197 · Cited by 67
Pulluri, B., Kumar, A., Shaheen, M. F., Jeter, J., & Sundararajan, S. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.006 · Cited by 65
Falvo, P., Orecchioni, S., Hillje, R., Raveane, A., Mancuso, P., Camisaschi, C., Luzi, L., Pelicci, P. G., & Bertolini, F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1818 · Cited by 65
de Lara, P. T., Cecconi, V., Hiltbrunner, S., Yagita∥, H., Friess, M., Bode, B., Opitz, I., Vrugt, B., Weder, W., Stolzmann, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1231 · Cited by 63
Kudo, M., Motomura, K., Wada, Y., Inaba, Y., Sakamoto, Y., Kurosaki, M., Umeyama, Y., Kamei, Y., Yoshimitsu, J., Fujii, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4072 · Cited by 62
Scholz, M. C., Yep, S., Chancey, M., Kelly, C., Chau, K., Turner, J., Lam, R. Y., & Drake, C. G. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s122497 · Cited by 59
Hwang, H. S., Cherukula, K., Bang, Y. J., Vijayan, V., Moon, M. J., Thiruppathi, J., Puth, S., Jeong, Y. Y., Park, I., Lee, S. E., et al. (2020) · Cells · doi:10.3390/cells9112432 · Cited by 59
Lutzky, J., Wolchok, J., Hamid, O., Lebbe, C., Pehamberger, H., Linette, G., de Pril, V., Ibrahim, R., Hoos, A., & O'Day, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9034 · Cited by 58 · cited 1×
“During the last decade, some clinical trials have indicated that monotherapy with ipilimumab (10 mg/ kg) in patients with advanced melanoma could result in improved OS rate [74], and a durable objective response [75].”
BackgroundBalar, A. V., Castellano, D., O’Donnell, P. H., Grivas, P. D., Vuky, J., Powles, T. B., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.284 · Cited by 58
Interferon‑γ induced PD‑L1 expression and soluble PD‑L1 production in gastric cancer
Imai, Y., Chiba, T., Kondo, T., Kanzaki, H., Kanayama, K., Ao, J., Kojima, R., Kusakabe, Y., Nakamura, M. R., Saito, T., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11757 · Cited by 57
PD-L1 regulation revisited: impact on immunotherapeutic strategies
Lucibello, G., Mograbi, B., Milano, G. A., Hofman, P. M., & Brest, P. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.005 · Cited by 57
Cappuccini, F., Stribbling, S. M., Pollock, E., Hill, A. V. S., & Redchenko, I. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1831-8 · Cited by 56
Omura, Y., Toiyama, Y., Okugawa, Y., Yin, C., Shigemori, T., Kusunoki, K., Kusunoki, Y., Ide, S., Shimura, T., Fujikawa, H., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02645-1 · Cited by 56
Zhou, M., Luo, C., Zhou, Z., Li, L., & Huang, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.029 · Cited by 56
Kang, B. W., & Chau, I. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000791 · Cited by 55
Parra, K., Valenzuela, P., Lerma, N., Gallegos, A., Reza, L. C., Rodriguez, G., Emmenegger, U., Desidero, T. D., Bocci, G., Felder, M. S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.429 · Cited by 54
Han, M., Wang, S., Zhao, W., Ni, S., Yang, N., Kong, Y., Huang, B., Chen, A., Li, X., Wang, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.002 · Cited by 54
Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2870-0 · Cited by 53
Song, Y., Liu, Q., Zuo, T., Wei, G., & Jiao, S. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104112 · Cited by 52
Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Miura, Y., Shiono, A., Nishihara, F., Murayama, Y., Noda, S., Kato, S., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13044 · Cited by 52
Veluswamy, P., Wacker, M., Scherner, M. P., & Wippermann, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218159 · Cited by 52
Li, J., Cong, L., Liu, J., Peng, L., Wang, J., Feng, A., Yue, J., Li, L., Wang, X., & Wang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594125 · Cited by 52
Keeping, S., Xu, Y., Chen, C.-I., Cope, S., Mojebi, A., Kuznik, A., Konidaris, G., Ayers, D., Sasane, M., Allen, R., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-0823 · Cited by 51
Yang, Y., Xu, W., Peng, D., Wang, H., Zhang, X., Wang, H., Xiao, F., Zhu, Y., Ji, Y., Gulukota, K., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.059 · Cited by 51
Choueiri, T. K., Atkins, M. B., Rose, T. L., Alter, R. S., Ju, Y., Niland, K., Wang, Y., Arbeit, R. D., Parasuraman, S., Gan, L., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01058-2 · Cited by 49
Ma, G., Li, C., Zhang, Z., Liang, Y., Liang, Z., Chen, Y., Wang, L., Li, D., Zeng, M., Shan, W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.697894 · Cited by 49
Combination of immune checkpoint inhibitors and radiotherapy: Review of the literature
Sindoni, A., Minutoli, F., Ascenti, G., & Pergolizzi, S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.003 · Cited by 48
Chen, Q., Xia, R., Zheng, W., Zhang, L., Li, P., Sun, X., & Shi, J. (2020) · PubMed · Cited by 47
Mohamad, O., de Leon, A. D., Schroeder, S. R., Leiker, A. J., Christie, A. L., Zhang-Velten, E. R., Trivedi, L. U., Khan, S. A., Desai, N. B., Laine, A. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440168 · Cited by 46
Mankor, J. M., Disselhorst, M. J., Poncin, M., Baas, P., Aerts, J. G. J. V., & Vroman, H. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.103040 · Cited by 45
Sakamuri, D., Glitza, I. C., Cuellar, S. L. B., Subbiah, V., Fu, S., Tsimberidou, A. M., Wheler, J. J., Hong, D. S., Naing, A., Falchook, G. S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0673 · Cited by 45
Gerritsen, W. R., van den Eertwegh, A. J. M., de Gruijl, T. D., van den Berg, H. P., Scheper, R. J., Sacks, N., Lowy, I., Stankevich, E., & Hege, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5146 · Cited by 44
Blake, Z., Marks, D. K., Gartrell, R. D., Hart, T. D., Horton, P., Cheng, S. K., Taback, B., Horst, B. A. J., & Saenger, Y. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0338-6 · Cited by 43
Khalife, E., Khodadadi, A., Talaeizadeh, A., Rahimian, L., Nemati, M., & Jafarzadeh, A. (2018) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2018.19.11.3019 · Cited by 43
Iwata, T. N., Sugihara, K., Wada, T., & Agatsuma, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222280 · Cited by 43
CTLA-4 Expression and Its Clinical Significance in Breast Cancer
Kern, R., & Panis, C. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00618-5 · Cited by 42
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F. C., Martignoni, M., Nathan, P., Powles, T. B., McDermott, D. F., Robbins, P. B., Chism, D. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4504 · Cited by 39
Stessin, A. M., Clausi, M. G., Zhao, Z., Lin, H., Hou, W., Jiang, Z., Duong, T. Q., Tsirka, S. E., & Ryu, S. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03459-y · Cited by 38
Giustini, N., & Bazhenova, L. A. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s235102 · Cited by 38
Avelumab: a new standard for treating metastatic Merkel cell carcinoma
Baker, M., Cordes, L. M., & Brownell, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1445528 · Cited by 37
High CTLA-4 expression correlates with poor prognosis in thymoma patients
Santoni, G., Amantini, C., Morelli, M. B., Tomassoni, D., Santoni, M., Marinelli, O., Nabissi, M., Cardinali, C., Paolucci, V., Torniai, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24645 · Cited by 37
Lu, G., Qiu, Y., & Su, X. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105606 · Cited by 36
Lafuente-Sanchis, A., Zúñiga, Á., Estors, M., Hernández, N. J. M., Cremades, A., Cuenca, M., & Galbis, J. M. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.010 · Cited by 34
Dorta-Estremera, S. M., Chin, R. L., Sierra, G., Nicholas, C., Yanamandra, A. V., Nookala, S. M. K., Yang, G., Singh, S., Curran, M. A., & Sastry, K. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0892 · Cited by 33
Kos, Š., Lopes, A., Véronique Préat, A., Čemažar, M., Tratar, U. L., Učakar, B., Vanvarenberg, K., Serša, G., & Vandermeulen, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217762 · Cited by 33
Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma
Agarwal, K., Yousaf, N., & Morganstein, D. L. (2020) · Clinical Medicine · doi:10.7861/clinmed.2018-0440 · Cited by 32
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
Cappuccini, F., Pollock, E., Stribbling, S., Hill, A. V. S., & Redchenko, I. (2017) · Oncotarget · doi:10.18632/oncotarget.17666 · Cited by 31
Pistillo, M. P., Carosio, R., Grillo, F., Fontana, V., Mastracci, L., Morabito, A., Banelli, B., Tanda, E. T., Cecchi, F., Dozin, B., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108428 · Cited by 31
Pembrolizumab in classical Hodgkin's lymphoma
Maly, J. J., & Alinari, L. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12770 · Cited by 30
Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice
Wang, F., Luo, Y., Tian, X., Ma, S., Sun, Y., You, C., Gong, Y. Q., & Xie, C. (2019) · Radiation Research · doi:10.1667/rr15182.1 · Cited by 30
Wainberg, Z. A., Höchster, H. S., Kim, E. J.-H., George, B., Kalyan, A., Chiorean, E. G., Waterhouse, D. M., Gutierrez, M. E., Parikh, A. R., Jain, R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.298 · Cited by 29
Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer
Regzedmaa, O., Li, Y., Li, Y., Zhang, H., Wang, J., Gong, H., Yin, Y., Li, W., Liu, H., & Chen, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s216362 · Cited by 29
Fu, D., Wu, J., Lai, J., Liu, Y., Zhou, L., Chen, L., & Zhang, Q. (2020) · PubMed · Cited by 29
PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
Kadam, P., & Sharma, S. P. (2020) · Vaccines · doi:10.3390/vaccines8020317 · Cited by 29
Kato, D., Yaguchi, T., Iwata, T., Morii, K., Nakagawa, T., Nishimura, R., & Kawakami, Y. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.68 · Cited by 28
Tobias, J., Battin, C., Linhares, A. D. S., Lebens, M., Baier, K., Ambroz, K., Drinić, M., Högler, S., Inić‐Kanada, A., Garner‐Spitzer, E., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00895 · Cited by 28
Pembrolizumab for the treatment of esophageal cancer
Yamamoto, S., & Kato, K. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1792881 · Cited by 28
Lopes, A., Vanvarenberg, K., Kos, Š., Lucas, S., Colau, D., den Eynde, B. J. V., Véronique Préat, A., & Vandermeulen, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-33933-7 · Cited by 27
Li, J., Wang, J.-H., Dingv, Y., Li, D., Wen, X., Zhao, J., Jiang, H., Liu, X., Huang, F., & Zhang, X. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03700-9 · Cited by 27
Du, B., Wen, X., Wang, Y., Lin, M., & Lai, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106694 · Cited by 26
Zhang, F., Huang, D., Zhao, L., Li, T., Zhang, S., Zhang, G., Yuan, F., Zhang, J., Zhang, Y., Zhao, Z., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936882 · Cited by 26
Salewski, I., Henne, J., Engster, L., Schneider, B., Lemcke, H., Skorska, A., Berlin, P., Henze, L., Junghanß, C., & Maletzki, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115990 · Cited by 25
Stark, F. C., Agbayani, G., Sandhu, J. K., Akache, B., McPherson, C., Deschatelets, L., Dudani, R., Hewitt, M., Jia, Y., Krishnan, L., et al. (2019) · Biomedicines · doi:10.3390/biomedicines7040091 · Cited by 24
Miyake, M., Hori, S., Owari, T., Oda, Y., Tatsumi, Y., Nakai, Y., Fujii, T., & Fujimoto, K. (2020) · Cancers · doi:10.3390/cancers12113153 · Cited by 24
Babiker, H. M., Braña, I., Mahadevan, D., Owonikoko, T. K., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K. P., Crittenden, M. R., Formenti, S. C., et al. (2021) · The Oncologist · doi:10.1002/onco.13810 · Cited by 24
Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu342.5 · Cited by 23
Kim, C., Kim, J. H., Kim, J. S., Chon, H. J., & Kim, J.-H. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e14228 · Cited by 23
Peng, M., Li, X., Gu, L., Weng, Y. M., Hu, M. X., & Song, Q. B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s177318 · Cited by 22
Yoo, S. Y., Badrinath, N., Jeong, S.-N., Woo, H. Y., & Heo, J. (2020) · Vaccines · doi:10.3390/vaccines8020321 · Cited by 22
Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy
Ni, J., & Ni, A. (2018) · Chinese Medical Sciences Journal · doi:10.24920/21804 · Cited by 21
Huang, J., Zhang, Y., Sheng, J., Zhang, H., Fang, W., Zhan, J., Zhou, T., Chen, Y., Liu, L., & Zhang, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s115262 · Cited by 20
Lin, P., Teng, W., Jeng, W., Lin, C., Lin, S., & Sheen, I. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001956 · Cited by 19
Stark, F. C., Weeratna, R. D., Deschatelets, L., Gurnani, K., Dudani, R., McCluskie, M. J., & Krishnan, L. (2017) · Vaccines · doi:10.3390/vaccines5040038 · Cited by 17
Schubert, P., Rutzner, S., Eckstein, M., Frey, B., Schweizer, C., Haderlein, M., Lettmaier, S., Semrau, S., Gostian, A., Zhou, J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576643 · Cited by 17
Pembrolizumab for the treatment of bladder cancer
Sundahl, N., Rottey, S., Maeseneer, D. J. D., & Ost, P. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1421461 · Cited by 16
Xu, Z., Feng, J., Weng, Y., Jin, Y., & Peng, M. (2021) · Journal of Oncology · doi:10.1155/2021/6631643 · Cited by 16
Simons, B. W., Cannella, F., Rowley, D., & Viscidi, R. P. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02493-z · Cited by 15
Larkin, J. M. G., Gordon, M. S., Thistlethwaite, F., Nathan, P. D., Rini, B. I., Martignoni, M., Shnaidman, M., Chiruzzi, C., Di Pietro, A., & Choueiri, T. K. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps4580 · Cited by 13 · cited 1×
“Avelumab also in combination with axitinib is now described as first-line treatment for patients with advanced RCC with manageable safety profile and substantial tolerability [111, 118].”
Background[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Guo, H., Bai, R., & Cui, J. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.02.05 · Cited by 12
Pembrolizumab use in bladder cancer: a tale of two trials
Aragon‐Ching, J. B. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00499-5 · Cited by 10
Ikushima, H., Sakatani, T., Ohara, S., et al. (2020) · Medicine · doi:10.1097/md.0000000000019956 · Cited by 9
Gibney, G. T., Weber, J. S., Kudchadkar, R. R., Conti, R. C. D., Tetteh, L. F., Eysmans, C. E., Yu, B., Martinez, A. J., & Younos, I. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.9056 · Cited by 7
Afzal, M. Z., & Shirai, K. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000265 · Cited by 6
Zaemes, J. P., Alzeer, A., Villa, K., & Atkins, M. B. (2020) · Immunotherapy · doi:10.2217/imt-2020-0139 · Cited by 6
Pellicciotta, I., Alouani, E. L., Raufi, A. G., Pan, S. M., Hu, J., & Manji, G. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.tps454 · Cited by 4
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
“Combining EMT inhibitors with immunotherapies, like immune checkpoint inhibitors, can bolster the immune system’s ability to fight cancer [32,53,61,77].”
BackgroundA comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Wu, X.-H., Wang, J.-Q., Wang, M.-D., Xiao, T., Wang, Y., Niu, J.-Y., Wang, L., Hou, D.-Y., Fu, B., Liu, Z., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122550 · Cited by 9
Metadata
- Authors
- Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M.
- Venue
- Cancer Cell International
- Published
- 2022-01-03
- Volume
- 22
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1475-2867 (ISSN-L)
- OpenAlex
- W4205315499
- Cited by
- 270
- References
- 302
- FWCI
- 20.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.